EloraTZP cut body weight by up to 23.3% and A1C by up to 2.9% at 48 weeks vs 14.8% and 2.4% with tirzepatide 15 mg in a phase 2b trial.
News|Articles|July 4, 2026
First Half 2026 Recap - Endocrinology
Author(s)Ryan Livingston
Fact checked by: Abigail Brooks, MA
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.
Advertisement
Advertisement
Endocrinology saw significant advancements throughout the first 6 months of 2026, between major approvals from the US Food and Drug Administration (FDA) and key trial readouts regarding everything from obesity to type 1 (T1D) and type 2 diabetes (T2D).
Related to this article
Newly published results from the TRIUMPH-1 study have indicated the direct correlation between the triple agonist and several improvements to weight.
Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Advertisement
Advertisement